Department of Optometry and Vision Science, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Centre for Optometry and Vision Science, Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
Ir J Med Sci. 2023 Dec;192(6):2777-2783. doi: 10.1007/s11845-023-03348-z. Epub 2023 Mar 29.
To evaluate the short-term effect of intravitreal bevacizumab (avastin) injection on visual outcomes of patients with diabetic macular oedema.
A retrospective cross-sectional study was conducted to evaluate 39 eyes of thirty-nine patients (mean age ± SD: 61.4 ± 15.0 years) that received intravitreal bevacizumab injection (1.25 mg in 0.05 ml) as treatment for diabetic macular oedema between January 2014 and July 2019 in Ghana. Data on visual acuity and central macular thickness before treatment and 6 weeks post-treatment were collected and analysed using paired t-test. Ordinary least squares linear regression analysis was also conducted to determine the relationship between improvement in visual acuity and central macular thickness after treatment and other predictor variables.
The mean ± SD visual acuity (LogMAR-equivalent of Snellen) of patients with diabetic macular oedema significantly improved from 0.84 ± 0.58 LogMAR before treatment to 0.69 ± 0.58 LogMAR at 6 weeks post-treatment (mean difference: 0.15 ± 0.32 LogMAR; 95% CI: 0.04 to 0.25; p = 0.01). Mean macular thickness ± SD on the other hand, reduced significantly (p < 0.001) from 316.54 ± 75.35 μm before treatment to 275.54 ± 57.43 μm after treatment. While age and worse pre-treatment visual acuity predicted improvement in visual acuity after treatment, a higher central macular thickness before treatment predicted an improvement in central macular thickness after intravitreal bevacizumab injection.
Treatment with intravitreal bevacizumab injection produces short-term improvement in vision and reduction in central macular thickness in African patients with diabetic macular oedema.
评估玻璃体内注射贝伐单抗（阿瓦斯汀）对糖尿病黄斑水肿患者视力结果的短期影响。
采用回顾性横断面研究，评估 2014 年 1 月至 2019 年 7 月期间在加纳接受玻璃体内注射贝伐单抗（1.25mg 于 0.05ml 中）治疗的 39 例 39 只眼（平均年龄±标准差：61.4±15.0 岁）的糖尿病黄斑水肿患者。收集并分析治疗前和治疗后 6 周的视力和中央黄斑厚度数据，并采用配对 t 检验进行分析。还进行了普通最小二乘线性回归分析，以确定治疗后视力和中央黄斑厚度的改善与其他预测变量之间的关系。
糖尿病黄斑水肿患者的平均±标准差视力（对数等效视力的 Snellen 视力）从治疗前的 0.84±0.58 LogMAR 显著改善至治疗后 6 周的 0.69±0.58 LogMAR（平均差异：0.15±0.32 LogMAR；95%置信区间：0.04 至 0.25；p=0.01）。另一方面，平均黄斑厚度±标准差从治疗前的 316.54±75.35μm 显著降低至治疗后的 275.54±57.43μm（p<0.001）。虽然年龄和治疗前视力较差预测治疗后视力改善，但治疗前中央黄斑厚度较高预测玻璃体内注射贝伐单抗后中央黄斑厚度改善。
在患有糖尿病黄斑水肿的非洲患者中，玻璃体内注射贝伐单抗治疗可产生短期视力改善和中央黄斑厚度降低。
